Apr 13, 2022 / 12:00PM GMT
Sarah Cue Kiely - ProQR Therapeutics N.V. - VP of IR & Corporate Communications
Thank you, operator, and good day, everyone. I'm Sarah Kiely, Vice President of Investor Relations and Corporate Communications at ProQR.
Today, we issued a press release announcing findings from additional analyses from the Phase II/III Illuminate trial of sepofarsen and an update on our corporate strategy. This press release can be found on our website at www.proqr.com.
With me today from the management team is Daniel de Boer, our Founder and CEO. Following his prepared remarks, we will have a Q&A session, which will include Daniel, along with Dr. Aniz Girach, our Chief Medical Officer; Gerard Platenburg, our Co-Founder and Chief Innovation Officer; and Smital Shah, our Chief Business and Financial Officer. (Operator Instructions)
During the call today, we will make forward-looking statements. There are risks and uncertainties associated with an investment in ProQR, which are described in detail in our SEC filings.
I
ProQR Therapeutics NV Additional Sepofarsen Analyses and Company Strategy Update Call Transcript
Apr 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers